Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.

Recs

2

5 Novartis Drugs You Need To Know About

Novartis  (NYSE: NVS  ) is one of the planet's top drug manufacturers and its 3% dividend yield makes it a staple in dividend investor portfolios.

However, Novartis is facing significant threats from competitors Biogen Idec (NASDAQ: BIIB  ) and Regeneron (NASDAQ: REGN  ) which could crimp sales even as generic competition heats up for Novartis' multi-billion blockbuster drug Diovan.

Source: Novartis

In the following slideshow, you'll learn more about Novartis' most important drugs and the threats and opportunities the lie ahead for them.

Novartis will have a tough time keeping up with these top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

 


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3041114, ~/Articles/ArticleHandler.aspx, 8/31/2015 6:12:54 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Todd Campbell
EBCapitalMarkets

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Today's Market

updated Moments ago Sponsored by:
DOW 16,528.03 -114.98 -0.69%
S&P 500 1,972.18 -16.69 -0.84%
NASD 4,776.51 -51.82 -1.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/31/2015 3:59 PM
BIIB $297.30 Down -6.39 -2.10%
Biogen Idec CAPS Rating: ****
NVS $97.22 Down -1.13 -1.15%
Novartis CAPS Rating: ****
REGN $513.50 Down -23.20 -4.32%
Regeneron Pharmace… CAPS Rating: ***